202 related articles for article (PubMed ID: 15522303)
1. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
2. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
3. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
[TBL] [Abstract][Full Text] [Related]
4. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
8. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
9. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
10. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
11. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
[TBL] [Abstract][Full Text] [Related]
12. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of interactions between urokinase plasminogen and inhibitors using molecular dynamic simulation and free-energy calculation.
Sa R; Fang L; Huang M; Li Q; Wei Y; Wu K
J Phys Chem A; 2014 Oct; 118(39):9113-9. PubMed ID: 24984238
[TBL] [Abstract][Full Text] [Related]
14. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
15. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
16. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
17. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
18. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases.
Katz BA; Luong C
J Mol Biol; 1999 Sep; 292(3):669-84. PubMed ID: 10497030
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Bhongade BA; Gouripur VV; Gadad AK
Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
[TBL] [Abstract][Full Text] [Related]
20. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]